DK1240905T3 - Acellulær pertussisvaccine med difteri- og tetanustoksoider - Google Patents

Acellulær pertussisvaccine med difteri- og tetanustoksoider

Info

Publication number
DK1240905T3
DK1240905T3 DK02075821T DK02075821T DK1240905T3 DK 1240905 T3 DK1240905 T3 DK 1240905T3 DK 02075821 T DK02075821 T DK 02075821T DK 02075821 T DK02075821 T DK 02075821T DK 1240905 T3 DK1240905 T3 DK 1240905T3
Authority
DK
Denmark
Prior art keywords
diphtheria
pertussis vaccine
acellular pertussis
tetanus toxoids
toxoids
Prior art date
Application number
DK02075821T
Other languages
English (en)
Other versions
DK1240905T5 (da
Inventor
Patrick Florent
Jean Stephenne
Christian Vandecasserie
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Application granted granted Critical
Publication of DK1240905T3 publication Critical patent/DK1240905T3/da
Publication of DK1240905T5 publication Critical patent/DK1240905T5/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K2039/10—Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DK02075821T 1996-11-07 1997-11-04 Acellulær pertussisvaccine med difteri- og tetanustoksoider DK1240905T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9623233.5A GB9623233D0 (en) 1996-11-07 1996-11-07 Vaccine composition
PCT/EP1997/006180 WO1998019702A1 (en) 1996-11-07 1997-11-04 Acellular pertussis vaccine with diphthriae- and tetanus-toxoids

Publications (2)

Publication Number Publication Date
DK1240905T3 true DK1240905T3 (da) 2005-07-18
DK1240905T5 DK1240905T5 (da) 2010-01-11

Family

ID=10802615

Family Applications (2)

Application Number Title Priority Date Filing Date
DK97950137T DK0941117T3 (da) 1996-11-07 1997-11-04 Acellulær pertussisvaccine med difteri- og tetanustoksoider
DK02075821T DK1240905T5 (da) 1996-11-07 1997-11-04 Acellulær pertussisvaccine med difteri- og tetanustoksoider

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK97950137T DK0941117T3 (da) 1996-11-07 1997-11-04 Acellulær pertussisvaccine med difteri- og tetanustoksoider

Country Status (30)

Country Link
EP (2) EP1240905B3 (da)
JP (1) JP3980652B2 (da)
KR (1) KR100518044B1 (da)
CN (1) CN1130226C (da)
AR (1) AR011509A1 (da)
AT (2) ATE222773T1 (da)
AU (1) AU710475B2 (da)
BR (2) BRPI9712917B8 (da)
CA (1) CA2271008C (da)
CO (1) CO4910171A1 (da)
CY (2) CY2407B1 (da)
CZ (1) CZ295954B6 (da)
DE (3) DE69715031T2 (da)
DK (2) DK0941117T3 (da)
ES (2) ES2182131T3 (da)
GB (1) GB9623233D0 (da)
HK (2) HK1022638A1 (da)
HU (1) HU224126B1 (da)
IL (1) IL129530A (da)
LU (1) LU91183I2 (da)
NO (2) NO320186B1 (da)
NZ (1) NZ335384A (da)
PL (1) PL188460B1 (da)
PT (2) PT941117E (da)
SA (1) SA98181128B1 (da)
SI (2) SI0941117T1 (da)
TR (1) TR199900979T2 (da)
TW (1) TW471971B (da)
WO (1) WO1998019702A1 (da)
ZA (1) ZA979984B (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1004314A1 (fr) * 1998-11-26 2000-05-31 Pasteur Merieux MSD Vaccin T.d. Polio rappel pour une population vaccinée ou sensibilisée
KR100374813B1 (ko) * 2000-04-07 2003-03-03 녹십자백신 주식회사 디프테리아, 파상풍 톡소이드, 정제백일해 및비형간염표면항원을 포함한 4가 혼합백신 및 그 제조 방법
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
KR100401423B1 (ko) * 2001-01-10 2003-10-17 주식회사 엘지생명과학 혼합 백신의 제조 방법
JP5007425B2 (ja) * 2006-01-30 2012-08-22 財団法人ヒューマンサイエンス振興財団 百日咳ワクチンの安全性評価方法
GB0616306D0 (en) * 2006-08-16 2006-09-27 Novartis Ag Vaccines
GB0822633D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Formulation
CN102844047B (zh) 2009-09-02 2017-04-05 诺华股份有限公司 含tlr活性调节剂的免疫原性组合物
US20120177681A1 (en) 2010-09-01 2012-07-12 Manmohan Singh Formulation of immunopotentiators
CA2828844C (en) 2011-03-02 2020-07-14 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
CN102363041A (zh) * 2011-11-17 2012-02-29 成都欧林生物科技股份有限公司 不含防腐剂疫苗的制作工艺
WO2013132041A2 (en) 2012-03-08 2013-09-12 Novartis Ag Adjuvanted formulations of booster vaccines
CN102793915B (zh) * 2012-07-25 2013-10-23 天津康希诺生物技术有限公司 一种无细胞百日咳疫苗的生产方法
CA2879939A1 (en) 2012-08-06 2014-02-13 Glaxosmithkline Biologicals S.A. Novel method
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
CN103100081A (zh) * 2012-12-26 2013-05-15 天津康希诺生物技术有限公司 一种多价联合疫苗
ES2597832T3 (es) 2013-03-08 2017-01-23 Janssen Vaccines & Prevention B.V. Vacuna acelular contra la tosferina
CA2919773A1 (en) 2013-08-05 2015-02-12 Glaxosmithkline Biologicals S.A. Combination immunogenic compositions
CN114748616A (zh) * 2022-05-23 2022-07-15 中国医学科学院医学生物学研究所 一种成人青少年用无细胞百白破联合疫苗及其制备方法
CN117417419B (zh) * 2023-01-10 2024-04-19 康希诺生物股份公司 一种百日咳毒素脱毒方法及无细胞百白破联合疫苗

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI861417A0 (fi) 1985-04-15 1986-04-01 Endotronics Inc Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav.
US4895800A (en) 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
ZA88488B (en) 1987-01-30 1988-10-26 Smith Kline Rit Hepatitis b virus surface antigens and hybrid antigens containing them
EP0304578B1 (en) 1987-06-22 2001-10-24 Medeva Holdings Bv Peptide comprising hepatitis B surface antigen
DE3789866T2 (de) 1987-07-17 1994-09-22 Rhein Biotech Proz & Prod Gmbh DNA-Moleküle, die für FMDH-Kontrollabschnitte und Strukturgene für ein Protein mit FMDH-Aktivität kodieren, sowie deren Anwendung.
SG48175A1 (en) 1989-07-25 1998-04-17 Smithkline Beecham Biolog Novel antigens and method for their preparation
GB9007024D0 (en) 1990-03-29 1990-05-30 Imperial College Novel vaccine
HU220236B (hu) 1992-05-23 2001-11-28 Smithkline Beecham Biologicals S.A. Hepatitis B felszíni antigént és egyéb antigéneket tartalmazó, kombinált oltóanyagok

Also Published As

Publication number Publication date
EP1240905B3 (en) 2009-08-26
HK1050473B (zh) 2006-03-03
EP1240905B1 (en) 2005-05-11
HK1022638A1 (en) 2000-08-18
ES2182131T3 (es) 2003-03-01
ATE222773T1 (de) 2002-09-15
HU224126B1 (hu) 2005-05-30
PL333127A1 (en) 1999-11-22
DE69733285T3 (de) 2010-03-25
TR199900979T2 (xx) 1999-07-21
NO992156L (no) 1999-05-04
DE69715031D1 (de) 2002-10-02
DK1240905T5 (da) 2010-01-11
NO2006005I1 (no) 2006-05-08
CY2407B1 (en) 2004-09-10
ES2240647T7 (es) 2010-03-31
DE69715031T2 (de) 2003-05-08
BR9712917A (pt) 1999-12-07
PL188460B1 (pl) 2005-02-28
IL129530A (en) 2005-11-20
JP3980652B2 (ja) 2007-09-26
CN1130226C (zh) 2003-12-10
BRPI9712917B1 (pt) 2019-12-03
NO2006005I2 (no) 2010-04-12
NO320186B1 (no) 2005-11-07
AR011509A1 (es) 2000-08-30
NO992156D0 (no) 1999-05-04
JP2001503422A (ja) 2001-03-13
DE69733285T2 (de) 2006-01-12
ZA979984B (en) 1998-07-23
HUP9904287A3 (en) 2001-05-28
CN1236321A (zh) 1999-11-24
ATE295178T1 (de) 2005-05-15
CA2271008C (en) 2008-07-22
DE69733285D1 (de) 2005-06-16
CZ164099A3 (cs) 1999-10-13
DE122005000046I1 (de) 2005-12-29
TW471971B (en) 2002-01-11
CZ295954B6 (cs) 2005-12-14
WO1998019702A1 (en) 1998-05-14
AU710475B2 (en) 1999-09-23
ES2240647T3 (es) 2005-10-16
SI1240905T1 (en) 2005-10-31
KR100518044B1 (ko) 2005-09-30
AU5319698A (en) 1998-05-29
BRPI9712917B8 (pt) 2021-05-25
SA98181128B1 (ar) 2006-03-25
DK0941117T3 (da) 2002-11-18
EP1240905A1 (en) 2002-09-18
SI0941117T1 (en) 2002-12-31
CO4910171A1 (es) 2000-04-24
PT941117E (pt) 2002-12-31
HUP9904287A1 (hu) 2000-04-28
NZ335384A (en) 2000-10-27
PT1240905E (pt) 2005-09-30
GB9623233D0 (en) 1997-01-08
LU91183I2 (fr) 2005-09-20
EP0941117A1 (en) 1999-09-15
CA2271008A1 (en) 1998-05-14
HK1050473A1 (en) 2003-06-27
CY2568B1 (en) 2008-07-02
EP0941117B1 (en) 2002-08-28
KR20000053092A (ko) 2000-08-25
IL129530A0 (en) 2000-02-29

Similar Documents

Publication Publication Date Title
DK0941117T3 (da) Acellulær pertussisvaccine med difteri- og tetanustoksoider
IL137809A0 (en) Pneumococcal and meningococcal vaccines formulated with interleukin-12
NO20026175D0 (no) Vaksinesammensetning
EP0958364A4 (en) IMMUNOTHERAPY AND IMPROVED Vaccines
BR9711853A (pt) Vacinas
EP0845270A4 (en) FUNCTIONAL FRAGMENT ANTIGEN OF TETANUS TOXIN, AND TETANUS VACCINE
IL149471A0 (en) Vaccines for mycoplasma bovis and methods for immunizing bovine amimals
HUP9701586A3 (en) Improved inactivated vaccines
MX9100654A (es) Vacuna contra haemophilus paragallinarum
AU2001269569A1 (en) Quadrivalent combination vaccine including diphtheria toxoid, tetanus toxoid, whole cell pertussis and hepatitis surface antigen, and preparation method thereof
GB9611673D0 (en) Meningococcal vaccine
ATE142697T1 (de) Impfstoff gegen bordetella pertussis
DE69729425D1 (de) Nicht-virulentes Mycoplasma synoviae und Impfstoffe desselben
SG73510A1 (en) Methods for producing enhanced antigenic enteric bacteria and vaccines comprising same
DK1027895T3 (da) Erysipelothrix rhusiopathiae-antigener og vaccinepræparater
ZA951239B (en) Melanoma associated antigenic polypeptide epitopes thereof and vaccines against melanoma